The role of TSLP and alarmins as early initiators of the inflammatory cascade in asthma pathogenesis has led to the development of novel targeted therapies, particularly against TSLP, with the aim of blocking the inflammatory pathway at the very beginning. This evidence concerns the gene TSLP and asthma.